What's in Ayman Magd Eldin Mohammad Sadek's pipeline?

Ayman Magd Eldin Mohammad Sadek has 3 drugs in our index: 3 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Ayman Magd Eldin Mohammad Sadek's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/ayman-magd-eldin-mohammad-sadek.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Ayman Magd Eldin Mohammad Sadek — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ayman Magd Eldin Mohammad Sadek pipeline: 3 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Area
Hybrid regimen	Hybrid regimen	marketed
Reverse hybrid regimen	Reverse hybrid regimen	marketed	Antiretroviral therapy	Infectious disease
Levofloxacin quadruple regimen	Levofloxacin quadruple regimen	marketed

Therapeutic area mix

Infectious disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Ayman Magd Eldin Mohammad Sadek:

Cite this brief

Drug Landscape (2026). Ayman Magd Eldin Mohammad Sadek — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ayman-magd-eldin-mohammad-sadek. Accessed 2026-06-10.